ATE549350T1 - Neuropeptid-2-rezeptor-agonisten - Google Patents

Neuropeptid-2-rezeptor-agonisten

Info

Publication number
ATE549350T1
ATE549350T1 AT06830133T AT06830133T ATE549350T1 AT E549350 T1 ATE549350 T1 AT E549350T1 AT 06830133 T AT06830133 T AT 06830133T AT 06830133 T AT06830133 T AT 06830133T AT E549350 T1 ATE549350 T1 AT E549350T1
Authority
AT
Austria
Prior art keywords
neuropeptide
receptor agonists
agonists
receptor
Prior art date
Application number
AT06830133T
Other languages
English (en)
Inventor
Karin Conde-Knape
Waleed Danho
George Ehrlich
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Rebecca Anne Taub
Jefferson W Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE549350T1 publication Critical patent/ATE549350T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT06830133T 2005-12-07 2006-11-27 Neuropeptid-2-rezeptor-agonisten ATE549350T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US85524906P 2006-10-30 2006-10-30
PCT/EP2006/068924 WO2007065808A2 (en) 2005-12-07 2006-11-27 Neuropeptide-2 receptor-agonists

Publications (1)

Publication Number Publication Date
ATE549350T1 true ATE549350T1 (de) 2012-03-15

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830133T ATE549350T1 (de) 2005-12-07 2006-11-27 Neuropeptid-2-rezeptor-agonisten

Country Status (18)

Country Link
US (2) US7642244B2 (de)
EP (1) EP1962959B1 (de)
JP (1) JP5000663B2 (de)
KR (1) KR101059602B1 (de)
AR (1) AR057222A1 (de)
AT (1) ATE549350T1 (de)
AU (1) AU2006324076A1 (de)
BR (1) BRPI0619573A2 (de)
CA (1) CA2630649A1 (de)
EC (1) ECSP088511A (de)
ES (1) ES2381497T3 (de)
IL (1) IL191636A (de)
MA (1) MA30142B1 (de)
NO (1) NO20082445L (de)
NZ (1) NZ568772A (de)
RU (2) RU2430108C2 (de)
TW (1) TWI321474B (de)
WO (1) WO2007065808A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
RU2430108C2 (ru) * 2005-12-07 2011-09-27 Ф.Хоффманн-Ля Рош Аг Агонисты рецептора нейропептида-2
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
WO2010052144A2 (en) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2477643A1 (de) * 2009-09-18 2012-07-25 Novo Nordisk A/S V2-rezeptoragonisten mit langzeitwirkung
IN2012DN03042A (de) * 2009-10-13 2015-07-31 Hoffmann La Roche
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
RU2013135175A (ru) * 2011-01-03 2015-02-10 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
EP3138578B1 (de) 2012-07-04 2022-01-12 F. Hoffmann-La Roche AG Anti-theophyllin-antikörper und verfahren zur verwendung davon
ES2604012T3 (es) 2012-07-04 2017-03-02 F. Hoffmann-La Roche Ag Conjugados de antígeno-anticuerpo unidos covalentemente
JP6247287B2 (ja) 2012-07-04 2017-12-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ビオチン抗体および使用方法
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
CA2933384A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MA43205A (fr) 2015-06-12 2018-09-19 Novo Nordisk As Composés pyy sélectifs et leurs utilisations
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
EP4058047A1 (de) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2-rezeptor-agonisten
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
SK121895A3 (en) * 1993-03-29 1996-10-02 Univ Cincinnati Analogues of peptide yy and uses thereof
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6380224B1 (en) * 1999-07-28 2002-04-30 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
JP2007512365A (ja) 2003-11-25 2007-05-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 選択的神経ペプチドｙ２受容体作動薬
WO2005080424A2 (en) 2004-02-23 2005-09-01 Rheoscience A/S Peptide yy analogues
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
RU2430108C2 (ru) * 2005-12-07 2011-09-27 Ф.Хоффманн-Ля Рош Аг Агонисты рецептора нейропептида-2
WO2007085887A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof

Also Published As

Publication number Publication date
JP5000663B2 (ja) 2012-08-15
US8268784B2 (en) 2012-09-18
WO2007065808A2 (en) 2007-06-14
BRPI0619573A2 (pt) 2011-10-04
CA2630649A1 (en) 2007-06-14
NZ568772A (en) 2010-05-28
KR20080082672A (ko) 2008-09-11
IL191636A0 (en) 2008-12-29
ES2381497T3 (es) 2012-05-28
WO2007065808A3 (en) 2007-08-02
JP2009518349A (ja) 2009-05-07
NO20082445L (no) 2008-09-03
IL191636A (en) 2012-10-31
AU2006324076A1 (en) 2007-06-14
RU2430108C2 (ru) 2011-09-27
US20100137223A1 (en) 2010-06-03
MA30142B1 (fr) 2009-01-02
RU2011105310A (ru) 2012-08-20
AR057222A1 (es) 2007-11-21
ECSP088511A (es) 2008-07-30
KR101059602B1 (ko) 2011-08-25
EP1962959A2 (de) 2008-09-03
TW200806311A (en) 2008-02-01
US7642244B2 (en) 2010-01-05
US20070135351A1 (en) 2007-06-14
EP1962959B1 (de) 2012-03-14
TWI321474B (en) 2010-03-11
RU2008127265A (ru) 2010-01-20

Similar Documents

Publication Publication Date Title
DE602006007563D1 (de) Agonisten
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
EP1931352A4 (de) Tlr-agonisten
DK1928882T3 (da) (s)-n-methylnaltrexon
DK3354273T3 (da) Melanocortinreceptorligander
ATE408603T1 (de) Pyrazolylcarboxanilide
EP1981902A4 (de) Nogo-rezeptorantagonisten
CR9974A (es) Gavión
DK1989196T3 (da) Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DE602006020447D1 (de) Niacin-rezeptoragonisten, zusammensetzungen mit de
ATE549324T1 (de) Tetrahydrobenzoxazine
DK1870409T3 (da) Benzimidazolforbindelser
ES1064680Y (es) Estructura portante de receptor
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502005005839D1 (de) Feldgeerät
DE102005052834B8 (de) Punktschweißklebverbindung
DE602006021285D1 (de) Mikrotomklinge
ATE485368T1 (de) Hiv - impfung
AT501523A3 (de) Estrich
DK1904404T3 (da) Mærkede uorganiske additiver
DE502006000445D1 (de) Mulchmähdeck
DE102006033170A8 (de) Einfassnähmaschine
DE502006002822D1 (de) Ges